Home
Loading

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

aVenture is in Alpha: During this preview period, you should expect the research data to be limited and may not yet meet our exacting standards. We've made the decision to provide early access to our data to showcase the product as we build, but you should not yet rely upon it alone for your investment decisions.

Get in touch

  • Contact

  • Request a demo

  • Request data updates

  • Add a company

Research

  • Companies

  • Investors

  • People

aVenture

  • Sitemap

  • Feature requests

Member

Backed by

© aVenture Investment Company, 2026. All rights reserved.

San Francisco, CA, USA

Privacy Policy

aVenture Investment Company ("aVenture") is an independent research platform providing detailed analysis and data on startups, venture capital investments, and key industry individuals. It is not a registered investment adviser, broker-dealer, or investment advisor and does not provide investment advice or recommendations. The data provided by aVenture does not constitute recommendations or advice, whether by methodology, analysis, AI-generated content, or a statement written by a staff member of aVenture.

aVenture is not affiliated with any of the people, companies, organizations, government agencies, regulatory bodies, or investment funds we provide coverage for on this site unless explicitly stated otherwise. Users assume full responsibility for decisions made based on information obtained from this platform. Links to external websites do not imply endorsement or affiliation with aVenture. Any links that provide the ability to invest in a primary or secondary transaction in a company are for convenience only and do not constitute solicitations or offers to buy or sell an investment. Investors should exercise heightened precaution and due diligence when investing in private companies, especially those not independently audited.

While we strive to provide valuable insights with objectivity and professional diligence, we cannot guarantee the accuracy of the information provided on our platform. Before making any investment decisions, you should verify the accuracy of all pertinent details for your decision. To the fullest extent permitted by law, aVenture shall not be liable for any direct, indirect, incidental, consequential, or financial damages arising from use of this site, whether by consumers of its contents directly or by persons or organizations covered by our research, even if we are advised of the possibility. Our best-efforts processes and correction request forms do not create a warranty or duty of care.

Profiles on this platform may include content generated in part by large language models (LLMs, artificial intelligence) that aggregate publicly available sources (e.g., SEC EDGAR, public filings, press releases). Source attribution is provided where known; always verify statements and claims here against original sources before relying on any data. Content on our site may contain inaccuracies, omissions, or what are commonly called 'hallucinations' if generated in part or in full by AI / LLMs. The risk can also exist even when content is written by a human, as internal and third-party sources may also have inaccuracies for the same or different reasons. While we randomly audit a proportion of content, this is not exhaustive.

We recommend that an independent auditor be hired to verify the accuracy of the information before relying on it for any sensitive decisions. By accessing this platform, you agree not to rely solely on any information generated by AI, aggregated, or sourced or written otherwise on this site, for investment, financial, or other decisions. aVenture assumes no responsibility for inaccuracies, omissions, or hallucinations. You must independently verify all data from primary sources. Use of this platform constitutes your waiver of claims for reliance-based damages, including negligent misrepresentation. To report an error, request a correction, or dispute information about a company or individual, contact us via our request data updates form.

Loading homepage
Loading
Home›Research›Companies

Companies

Loading
Home›
Research›
Companies›
Evia Bio
AddedFeb 19, 2024
UpdatedJun 18, 2026
Evia Bio

Evia Bio

Angel

Evia Bio, a Minneapolis-based software company, innovates non-DMSO cryopreservation tech for cell therapy.

HQ
Minneapolis, MN, US
Founded
2019
Overview
Compare
Fundraising
Employees
Website

Evia Bio, founded in Minneapolis, Minnesota, is a life sciences innovation company dedicated to advancing cryopreservation technologies. Its core mission is to develop non-DMSO cryopreservation solutions for the cell therapy industry, aiming to enhance the viability and performance of preserved cells. The company offers a range of products and services including CryoConnect, CryoChats™, CryoX™, CryoU, and CryoToons™, which focus on assessing and improving current cryopreservation protocols through AI-driven, non-toxic cryoprotectant platforms.

Evia Bio has attracted notable investors and experts in the life sciences field, contributing to its rapid growth and innovation. The company has achieved significant milestones in developing non-DMSO cryoprotectants that are safer and more effective than traditional methods. Its impact on the cell therapy industry is profound, providing critical advancements that improve the quality and longevity of preserved cells, thereby enhancing therapeutic outcomes.

Evia Bio - Quick Facts

When was Evia Bio founded?

Evia Bio was founded in 2019.

Where is Evia Bio's headquarters located?

Evia Bio's headquarters is located in Minneapolis, MN, US.

When was Evia Bio's last funding round?

Evia Bio's most recent funding round was for $10k (USD) in December 2022.

How much has Evia Bio raised to-date?

As of Dec 6, 2022, Evia Bio has raised a total of $260k (USD).

How many employees does Evia Bio have?

Evia Bio has 7 employees as of Feb 4, 2024.

Evia Bio - Classification

Industry
  • Professional Service Companies
Ownership
  • Private
  • Venture Capital
Technology
  • AI
Geographic Exposure
  • United States
Revenue
  • Recurring
  • Software
Customer
  • Enterprise
Main Product
  • Cell Therapy
  • Cryopreservation
Tags
  • Biotech
  • Consulting
  • Healthtech
NAICS
  • 540000Professional, Scientific, and Technical Services
  • 541500Computer Systems Design and Related Services
  • 541000Professional, Scientific, and Technical Services
  • 541510Computer Systems Design and Related Services
  • 541511Custom Computer Programming Services
SIC
  • 7300Business Services
  • 7370Computer Programming, Data Processing, And Other Computer Related
  • 7371Computer Programming Services
Show 9 more industry codes
NAICS
  • 513200Software Publishers
  • 510000Information
  • 620000Health Care and Social Assistance
  • 513000Publishing Industries
  • 513210Software Publishers
SIC
  • 8000Health Services
  • 8040Offices And Clinics Of Other Health Practitioners
  • 7372Prepackaged Software
  • 8049Offices And Clinics Of Health Practitioners, Not Elsewhere Classified